Christopher Pinahs Joins Robins Kaplan’s Intellectual Property and Technology Group

April 14, 2017

Christopher Pinahs recently joined Robins Kaplan LLP’s Intellectual Property and Technology Litigation Group, where he focuses his practice on patent and trademark litigation. Applying his background in the biological sciences, Pinahs has extensive experience representing clients in the pharmaceutical, medical device, and agricultural arts. In all arenas, Pinahs uses his technical background to help clients develop their case and implement an appropriate strategy to achieve their business goals.

Pinahs’ trial experience includes several significant cases in the health and life sciences industry, including the representation of a generic manufacturer in its challenge of several patents directed to Purdue’s multibillion-dollar OxyContin® product. More recently, Pinahs was a member of a trial team that prevailed on several patents directed to the Alzheimer’s drug, Namenda XR®.

While attending classes at the University of Minnesota Law School, Pinahs simultaneously studied to earn his master’s degree in plant biological studies. He received his J.D. in 2011, and his M.S. in 2012.

Pinahs is active in the legal community, and his involvement includes pro bono representation through the Pro Se Project. He previously served as the chair of the Intellectual Property Practice Group for the Minnesota Federal Bar Association (2015-2016), and currently serves as a member of the Grants Committee for the Minnesota Federal Bar Association.

Related Publications

September 22, 2020
Herbal Patent Protection
Shui Li - 闻宁阁 American Intellectual Property
August 26, 2020
INSIGHT: Avoiding Trade Secret Claims After Seeing a Competitor’s Crown Jewels
Jake Holdreith, David Prange, Emily Tremblay - Bloomberg Law
July 2020
Hatch-Waxman Patent Litigation Strategies
Jeffrey Alan Hovden - LexisNexis
June 2020
Trade Secrets: Safe as Houses
Christopher Larus, David Prange, Alyssa Bixby-Lawson - Intellectual Property Magazine
Back to Top